1.52
price up icon7.53%   +0.06
 
loading

Nextcure Inc 주식(NXTC)의 최신 뉴스

Piper Sandler maintains Overweight on NextCure stock after positive trial results - Investing.com India

pulisher
Investing.com India

Piper Sandler maintains Overweight on NextCure stock after positive trial results By Investing.com - Investing.com Canada

pulisher
Investing.com Canada

Piper Sandler maintains Overweight on NextCure stock after positive trial results By Investing.com - Investing.com Australia

pulisher
Investing.com Australia

Piper Sandler maintains Overweight on NextCure stock after positive trial results By Investing.com - Investing.com

pulisher
Investing.com

Piper Sandler maintains Overweight on NextCure stock after positive trial results By Investing.com - Investing.com UK

pulisher
Investing.com UK

NextCure (NASDAQ:NXTC) Given Buy Rating at HC Wainwright - Defense World

pulisher
Defense World

Immunotherapies break into cold colorectal cancers at ASCO - BioCentury

pulisher
BioCentury

Colorectal Cancer Market to Exhibit Moderate Growth Rate During by 2032, Investigates DelveInsight - EIN News

pulisher
EIN News

Daily Market Movement: Nextcure Inc (NXTC) Sees a -3.73 Decrease, Closing at 1.55 – DWinneX - The Dwinnex

pulisher
The Dwinnex

Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year - Yahoo New Zealand News

pulisher
Yahoo New Zealand News

Advanced Gastric Carcinoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and ... - openPR

pulisher
openPR

The Globe and Mail - The Globe and Mail

pulisher
The Globe and Mail

Reflecting on NextCure's (NASDAQ:NXTC) Share Price Returns Over The Last Year - Yahoo New Zealand News

pulisher
Yahoo New Zealand News

HC Wainwright Reiterates Buy Rating for NextCure (NASDAQ:NXTC) - Defense World

pulisher
Defense World

Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors - Yahoo Finance UK

pulisher
Yahoo Finance UK

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

pulisher
GlobeNewswire Inc.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

pulisher
GlobeNewswire Inc.

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 - GlobeNewswire

pulisher
GlobeNewswire

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

pulisher
GlobeNewswire Inc.

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

pulisher
GlobeNewswire Inc.

Small biotechs reveal reliance on Chinese CDMOs - BioCentury

pulisher
BioCentury

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

pulisher
Seeking Alpha

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St

pulisher
Simply Wall St

NextCure Inc to Engage with Investors in Informal Talks - TipRanks.com - TipRanks

pulisher
TipRanks

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

pulisher
GlobeNewswire Inc.

NextCure to lay off 37% of staff, dial back research plans - Yahoo Finance

pulisher
Yahoo Finance

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

pulisher
GlobeNewswire Inc.

The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies - Science

pulisher
Science

COPD research sees potential in an anti-inflammatory protein - COPD News Today

pulisher
COPD News Today

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

pulisher
GlobeNewswire Inc.

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem - Pharmaceutical Technology

pulisher
Pharmaceutical Technology

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

pulisher
Zacks Investment Research

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing - Yahoo Finance

pulisher
Yahoo Finance

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

pulisher
GlobeNewswire Inc.

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

pulisher
Zacks Investment Research

NextCure (NXTC) Down on Shelving Plans to Develop Candidate - Yahoo Finance

pulisher
Yahoo Finance

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

pulisher
Benzinga

US Stocks Higher; Initial Jobless Claims Fall To 202,000

pulisher
Benzinga

NextCure Provides Year-End Clinical Pipeline Updates

pulisher
GlobeNewswire Inc.

US Stocks Higher; Initial Jobless Claims Fall To 202,000 - Cepton (NASDAQ:CPTN), Amtech Systems (NASDAQ:A - Benzinga

pulisher
Benzinga

Advanced Gastric Carcinoma Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Developing ... - GlobeNewswire

pulisher
GlobeNewswire

Cancer-focused biotech company Imvax raised $23M to advance clinical trials - Technical.ly

pulisher
Technical.ly

Imvax Provides Corporate Update - Business Wire

pulisher
Business Wire

Ashley Anne Martz Michael Felix Muzza | News, Sports, Jobs - Jamestown Post Journal

pulisher
Jamestown Post Journal

NextCure, Underwriters Win Dismissal of Investor Class Action - Bloomberg Law

pulisher
Bloomberg Law

Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in ... - PR Newswire

pulisher
PR Newswire

Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market ... - GlobeNewswire

pulisher
GlobeNewswire

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer - Business Wire

pulisher
Business Wire

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors - citybiz

pulisher
citybiz

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the ... - PR Newswire

pulisher
PR Newswire
$83.72
price down icon 1.00%
$26.37
price down icon 1.49%
$165.77
price down icon 1.49%
$158.79
price down icon 0.19%
$386.75
price up icon 1.23%
$95.30
price down icon 2.67%
자본화:     |  볼륨(24시간):